JP2008531574A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531574A5
JP2008531574A5 JP2007557126A JP2007557126A JP2008531574A5 JP 2008531574 A5 JP2008531574 A5 JP 2008531574A5 JP 2007557126 A JP2007557126 A JP 2007557126A JP 2007557126 A JP2007557126 A JP 2007557126A JP 2008531574 A5 JP2008531574 A5 JP 2008531574A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
nhr
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007557126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531574A (ja
JP5055136B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/006283 external-priority patent/WO2006091671A1/en
Publication of JP2008531574A publication Critical patent/JP2008531574A/ja
Publication of JP2008531574A5 publication Critical patent/JP2008531574A5/ja
Application granted granted Critical
Publication of JP5055136B2 publication Critical patent/JP5055136B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007557126A 2005-02-24 2006-02-23 Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物 Expired - Fee Related JP5055136B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
US60/655,981 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (3)

Publication Number Publication Date
JP2008531574A JP2008531574A (ja) 2008-08-14
JP2008531574A5 true JP2008531574A5 (enExample) 2009-04-02
JP5055136B2 JP5055136B2 (ja) 2012-10-24

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557126A Expired - Fee Related JP5055136B2 (ja) 2005-02-24 2006-02-23 Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物

Country Status (33)

Country Link
US (1) US7666879B2 (enExample)
EP (1) EP1904494B1 (enExample)
JP (1) JP5055136B2 (enExample)
KR (1) KR100904938B1 (enExample)
CN (1) CN101128461B (enExample)
AR (1) AR056186A1 (enExample)
AT (1) ATE490254T1 (enExample)
AU (1) AU2006216710B2 (enExample)
BR (1) BRPI0609047A2 (enExample)
CA (1) CA2599124C (enExample)
CR (1) CR9331A (enExample)
CY (1) CY1111154T1 (enExample)
DE (1) DE602006018615D1 (enExample)
DK (1) DK1904494T3 (enExample)
DO (1) DOP2006000051A (enExample)
EA (1) EA011691B1 (enExample)
ES (1) ES2354716T3 (enExample)
HR (1) HRP20100677T1 (enExample)
IL (1) IL184717A (enExample)
MA (1) MA29433B1 (enExample)
MX (1) MX2007010326A (enExample)
NO (1) NO20074666L (enExample)
NZ (2) NZ584753A (enExample)
PE (1) PE20061098A1 (enExample)
PL (1) PL1904494T3 (enExample)
PT (1) PT1904494E (enExample)
RS (1) RS51590B (enExample)
SI (1) SI1904494T1 (enExample)
TN (1) TNSN07323A1 (enExample)
TW (1) TW200640924A (enExample)
UA (1) UA91535C2 (enExample)
WO (1) WO2006091671A1 (enExample)
ZA (1) ZA200707136B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679408B (zh) * 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
EA201000615A1 (ru) 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
CN104822679B (zh) * 2012-11-29 2016-10-19 霍夫曼-拉罗奇有限公司 咪唑并吡啶衍生物
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
AU2014365823B2 (en) 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en) 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
DK3169671T3 (da) 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
US10160747B2 (en) * 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
US11512088B2 (en) * 2019-01-30 2022-11-29 Avista Pharma Solutions, Inc. Synthetic process and intermediates
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
US12365685B2 (en) 2019-02-18 2025-07-22 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
EP3990458A4 (en) * 2019-06-25 2025-01-08 Sinopsee Therapeutics LINKS TO THE TREATMENT OF CANCER
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
JP7891524B2 (ja) 2021-08-11 2026-07-16 バイオメア フュージョン,インコーポレイテッド 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤
MX2024002189A (es) 2021-08-20 2024-06-11 Biomea Fusion Inc Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888310B1 (en) 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
ES2284887T3 (es) 2001-07-11 2007-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para tratar enfermedades transmitidas por citocinas.
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
US7125888B2 (en) * 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
WO2005016928A1 (ja) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体

Similar Documents

Publication Publication Date Title
HRP20100677T1 (hr) IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2
JP2013505969A5 (enExample)
JP2013540712A5 (enExample)
JP2013537203A5 (enExample)
JP2014508811A5 (enExample)
JP2013510120A5 (enExample)
JP2013529210A5 (enExample)
JP2011519854A5 (enExample)
JP2010504344A5 (enExample)
JP2009529541A5 (enExample)
JP2013531031A5 (enExample)
JP2013542218A5 (enExample)
JP2010510231A5 (enExample)
JP2013534248A5 (enExample)
JP2012041349A5 (enExample)
JP2014515406A5 (enExample)
JP2009535307A5 (enExample)
JP2008501000A5 (enExample)
JP2009514870A5 (enExample)
JP2014508804A5 (enExample)
JP2013544854A5 (enExample)
JP2014505107A5 (enExample)
JP2009513658A5 (enExample)
JP2013544276A5 (enExample)
JP2017526677A5 (enExample)